Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Larkin

Showing results (381-390 of 399) with videos related to

Pageof 40
Sort By:
Clinical Spine Surgery|March 16, 2024
Radiology Reports Do Not Accurately Portray the Severity of Cervical Neural Foraminal StenosisYunsoo Lee, Tariq Ziad Issa, Aditya S Mazmudar, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patientsC Robert, G V Long, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Oncogene|March 3, 2015
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repairN Kanu, E Grönroos, P Martinez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialT K Choueiri, K Penkov, H Uemura, et al.
The Lancet. Oncology|October 23, 2018
Integration of oncology and palliative care: a Lancet Oncology CommissionStein Kaasa, Jon H Loge, Matti Aapro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Acta Neuropathologica Communications|June 2, 2016
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic studyDonato Iacovazzo, Richard Caswell, Benjamin Bunce, et al.
BMC Palliative Care|December 29, 2021
Effectiveness of a nurse-delivered (FOCUS+) and a web-based (iFOCUS) psychoeducational intervention for people with advanced cancer and their family caregivers (DIAdIC): study protocol for an international randomized controlled trialOrphé Matthys, Aline De Vleminck, Sigrid Dierickx, et al.
Pageof 40

Showing results (381-390 of 399) with videos related to

Sort By:
Pageof 40
Clinical Spine Surgery|March 16, 2024
Radiology Reports Do Not Accurately Portray the Severity of Cervical Neural Foraminal StenosisYunsoo Lee, Tariq Ziad Issa, Aditya S Mazmudar, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patientsC Robert, G V Long, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Oncogene|March 3, 2015
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repairN Kanu, E Grönroos, P Martinez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialT K Choueiri, K Penkov, H Uemura, et al.
The Lancet. Oncology|October 23, 2018
Integration of oncology and palliative care: a Lancet Oncology CommissionStein Kaasa, Jon H Loge, Matti Aapro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Acta Neuropathologica Communications|June 2, 2016
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic studyDonato Iacovazzo, Richard Caswell, Benjamin Bunce, et al.
BMC Palliative Care|December 29, 2021
Effectiveness of a nurse-delivered (FOCUS+) and a web-based (iFOCUS) psychoeducational intervention for people with advanced cancer and their family caregivers (DIAdIC): study protocol for an international randomized controlled trialOrphé Matthys, Aline De Vleminck, Sigrid Dierickx, et al.
Pageof 40